יומירה 40 מ"ג
abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pen - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r
מידולם 1 מגמל
rafa laboratories ltd - midazolam - תמיסה להזרקה - midazolam 1 mg/ml - midazolam - midazolam - premedication before induction of anesthesia (i.m). basal sedation before diagnostic or surgical interventions carried out under local anesthesia (i.v. administration). induction and maintenance of anesthesia. as an induction agent in inhalation anesthesia or a sleep-inducing component in combined anesthesia, including total intravenous anesthesia (i.v. injection, i.v. infusion). ataralgesia in combination with ketamine in children (i.m. administration). status epilepticus.
מידולם 5 מגמל
rafa laboratories ltd - midazolam - תמיסה להזרקה - midazolam 5 mg/ml - midazolam - midazolam - premedication befor induction of anesthesia (i.m). basal sedation before diagnostic or surgical interventions carried out under local anesthesia (i.v. administration). induction and maintenance of anesthesia. as an induction agent in inhalation anesthesia or a sleep-inducing component in combined anesthesia, including total intravenous anesthesia (i.v. injection, i.v. infusion). ataralgesia in combination with ketamine in children (i.m. administration).status epilepticus.
יומירה 40 מ"ג
abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pfs - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r
יומירה 40 מ"ג
abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - vial - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r
וילאט 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii
וילאט 500
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii
פרינג'קט
cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.
פרינג'קט
cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial
פרינג'קט
cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial